Coulter demonstrates the virtues of waiting

As promised, Coulter Pharmaceutical Inc. signed a commercialization agreement before year end for its Bexxar antibody that will allow the company to build an oncology sales presence in the U.S.

The deal announced Friday with SmithKline Beecham is worth up to $117.5 million to CLTR - excluding a $15 million credit line from the pharma company, profit-sharing in the U.S. and royalties - demonstrating that big pharma will pay handsomely for a late-stage product that works...